6 nominees · 3 ballot items.
Proposal 1: Approve amendment and restatement of the charter to allow up to fifteen 1-month extensions of the Combination Period from July 15, 2026 to October 15, 2027; Proposal 2: Approve amendment to the Trust Agreement to permit monthly extension fees (lesser of $100,000 or $0.033 per remaining public share) to extend the Combination Period up to fifteen 1-month extensions from July 15, 2026 to October 15, 2027; Proposal 3: Authorize the Chairman to adjourn the Extraordinary General Meeting to later date(s) as necessary.
Amend and restate the Company’s charter to extend the deadline to consummate a business combination by permitting up to fifteen additional one-month extensions, moving the termination date from July 15, 2026 to October 15, 2027, by adopting the Second A&R Charter (Annex A).
The Charter Amendment Proposal asks shareholders to approve a special resolution to amend and restate the Company’s Amended and Restated Memorandum and Articles of Association (the "Existing Charter") to permit the Company to extend its Combination Period beyond the current Termination Date of July 15, 2026 up to October 15, 2027 by adopting a Second Amended and Restated Charter (the "Second A&R Charter") set forth in Annex A. Management is seeking approval because the board believes there is insufficient time before July 15, 2026 to consummate a business combination and additional time is necessary to complete the HZJL Business Combination and any other potential combinations. The extension would allow up to fifteen (15) additional one-month extensions, each initiated upon five days' advance notice and funded by loans from the Sponsor or its affiliates in the form of Monthly Extension Fees deposited into the Trust Account for each extension. The board recommends a vote FOR the Charter Amendment because without it the Company could be forced to liquidate, which would extinguish the interests of public shareholders and render founder and private units worthless; approving the amendment preserves the opportunity to consummate a Business Combination. Key governance considerations include the conditionality of the extension (both the Charter and Trust Agreement amendments must be approved for extensions beyond the current rights), the Sponsor’s funding commitment via interest-free loans repayable upon a successful Business Combination but forgivable if no combination occurs, and the potential dilution/reduction of trust account funds available for redemption as extension fees or redemptions occur. The proposal is subject to a special resolution (two-thirds majority) and the Board has unanimously recommended FOR approval. Investors should weigh the benefit of potential business combination value creation against the risk that extensions and associated redemptions may deplete trust funds and that the sponsor’s incentives and related-party interests could diverge from public shareholders’ interests.
Amend the Trust Agreement to allow monthly extensions up to fifteen additional one-month periods through October 15, 2027, with the Sponsor depositing for each extension the Monthly Extension Fee equal to the lesser of $100,000 per month for all remaining public shares or $0.033 per remaining public share (Annex B).
The Trust Agreement Amendment Proposal seeks shareholder approval to amend the Company’s investment management trust agreement (the "Trust Agreement") to permit the Company to fund monthly one-month extensions of its Combination Period up to fifteen times, moving the Extended Date to October 15, 2027, by depositing a Monthly Extension Fee into the Trust Account for each extension. The Monthly Extension Fee is defined as the lesser of $100,000 per month for all remaining public shares or $0.033 per remaining public share after accounting for redemptions. Management is pursuing this vote to secure a funding mechanism (provided by the Sponsor or its affiliates as loans to the Company) that enables the Company to continue to pursue a Business Combination beyond July 15, 2026 and to align the trust accounting mechanics with the charter amendment. Approval requires a simple majority (50% of votes cast) under the Trust Agreement. The board recommends FOR because the amendment provides a practicable and limited-cost way to gain additional time to complete the HZJL Business Combination; it mitigates immediate liquidation risk. The transaction raises governance considerations, including the Sponsor’s role in funding the extensions via recoverable, non-interest-bearing loans and the risk that repeated extensions and redemptions will deplete the Trust Account, potentially undermining the economic protections of public shareholders. The amendment also conditions the Company’s ability to extend on shareholder approval and does not obligate the Sponsor to fund extensions beyond its discretion; investors should consider the Sponsor’s track record and incentives and the possibility that the Sponsor may choose not to fund extensions despite shareholder approval.
Authorize the Chairman to adjourn the Extraordinary General Meeting to one or more later dates as necessary or appropriate to allow further solicitation of proxies.
The Adjournment Proposal requests an ordinary resolution (simple majority) authorizing the chairman to adjourn the Extraordinary General Meeting to later date(s) as the chairman deems necessary to permit additional solicitation of proxies or otherwise facilitate the approval of the Charter Amendment and Trust Agreement Amendment proposals. Management recommends voting FOR to preserve the board’s flexibility to seek additional votes if required. The proposal is routine in governance practice, but important for procedural completion of the two conditioned proposals and to enable the board to avoid having all proposals fail if initial vote counts are insufficient. The potential consequence for shareholders is primarily timing and the possibility of continued uncertainty; adjournment alone does not change substantive rights but could allow additional outreach to shareholders and greater chance of approval of the primary proposals.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Karpus Management, Inc.Activist | 12.38% | 736,550 | $8M |
| 2 | RIVERNORTH CAPITAL MANAGEMENT, LLC | 8.31% | 494,487 | $5M |
| 3 | Westchester Capital Management, LLC | 6.18% | 367,500 | $4M |
| 4 | AQR Arbitrage LLC | 5.84% | 347,804 | $4M |
| 5 | GLAZER CAPITAL, LLC | 5.50% | 327,439 | $3M |
| 6 | D. E. Shaw Co., Inc.Activist | 4.59% | 273,125 | $1M |
| 7 | GOLDMAN SACHS GROUP INC | 2.37% | 140,776 | $674K |
| 8 | Clear Street Group Inc. | 0.54% | 32,305 | $340K |
| 9 | UBS Group AG | 0.00% | 122 | $584 |
| 10 | MORGAN STANLEY | 0.00% | 64 | $307 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.